"We have suffered a significant financial loss as a consequence of Vifor's conduct," says Pharmacosmos
The Swiss firm has demonstrated anticompetitive behavior for 12 years on markets where it competes with Pharmacosmos, claims the Danish firm after having officially complained to the EU Commission.
by mikkel aabenhus hemmingsen & christopher due karlsson, translated by daniel pedersen
For years on end, Vifor Pharma has been shutting out Pharmacosmos from the intravenous (IV) iron deficiency drug market, says the Danish family-owned business, claiming it has consequently lost out on considerable income.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
